Protecting Free Vaccines Act of 2025

WHAT HAPPENED: Senator Wyden (D-OR) and Senator Sanders (I-VT) introduced S.2857, the 'Protecting Free Vaccines Act of 2025,' on September 18, 2025. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions. It is in the earliest legislative stage with no hearings, markups, or floor votes. A companion bill (HR5448) was introduced in the House and referred to three committees. The bill has only 2 cosponsors in the Senate. THE MONEY TRAIL: This bill authorizes zero dollars. It is a regulatory mandate, not an appropriations bill. The mechanism requires group health plans and health insurance issuers to cover ACIP-recommended immunizations without cost-sharing for plan years before January 1, 2030. This is a codification of existing ACA preventive services requirements (Section 2713 of the PHSA). No new funding is created; no tax credits, grants, or procurement programs are established. The financial impact is a transfer of liability from patients to insurers for vaccines that are already covered — a neutral shift because these mandates are already in effect under the ACA. STRUCTURAL WINNERS AND LOSERS: Vaccine manufacturers (PFE, MRNA, JNJ) see no change in revenue outlook because the bill does not add new vaccines to the ACIP list, expand the covered population (e.g., adults without insurance), or increase per-unit pricing. Health insurers (UNH, ELV) already comply with the ACA's preventive services mandate; this bill simply codifies it in statute. CVS Health's pharmacy business benefits from maintaining current vaccine administration volumes but gains no new customer base. The only 'winner' is the entire sector's regulatory stability — the bill prevents a potential future administration from eliminating these coverage requirements via regulatory guidance. The downside risk removed is modest; the upside is non-existent. REAL MARKET DATA TRENDS: All tracked stocks are declining over the past 30 days: PFE (-5.44%), MRNA (-5.20%), JNJ (-6.24%), CVS (+19.62% over 30 days but driven by broader healthcare trends, not vaccine policy). MRNA has collapsed 13.49% in the last 7 days alone due to company-specific factors (waning COVID vaccine demand, pipeline setbacks). UNH (+41.62% in 30 days) and ELV (+32.25%) are surging on unrelated managed care fundamentals. This bill has zero connection to any of these price movements. The stock trends are irrelevant to this legislative action. TIMELINE: The bill has only 2 cosponsors, no Senate HELP Committee hearing scheduled, and no House companion markup. Passage probability in the 119th Congress is low without broader bipartisan support or inclusion in must-pass healthcare legislation. The sunsets (plan years before January 1, 2030) suggest this is a placeholder bill. Market-moving progress would require a committee markup, floor votes in either chamber, or attachment to a year-end omnibus package — none of which are currently visible.